Literature DB >> 15986915

Prevalence of serum antibodies to canine adenovirus and canine herpesvirus in the European red fox (Vulpes vulpes) in Australia.

A J Robinson1, S K Crerar, N Waight Sharma, W J Müller, M P Bradley.   

Abstract

OBJECTIVES: To determine the seroprevalence and aspects of the epidemiology of canine adenovirus (CAdV) and canine herpesvirus (CaHV-1) in European red foxes (Vulpes vulpes) in Australia.
DESIGN: Serum samples were collected opportunistically from foxes in 1991-1994 in Western Australia (WA) and South Australia (SA) and in 1980-1984 and 1990-1994 in New South Wales (NSW) and the Australian Capital Territory (ACT). The sera were examined for antibody to CAdV and CaHV-1 using ELISAs. Seroprevalence in the different regions was determined for both viruses and the CAdV data were analysed for interactions between decade of collection, age, season, region and gender using logistic regression.
RESULTS: The overall prevalence of antibody to CAdV was 23.2% (308/1326) but was significantly higher in sera collected in the eastern states of Australia (47%: 233/498) than in WA (9%: 75/828). Overall, in NSW and the ACT, there was a significantly lower prevalence in juveniles than in adults and the prevalence in juveniles in the 1990s was significantly lower than in the 1980s. The prevalence was also significantly lower in the autumn than in the winter for juveniles but the reverse held for adults. The NSW and ACT data were subdivided into eastern (including the ACT) and western regions. This revealed a significantly higher prevalence in the winter than in the autumn for the west and the reverse in the east. In WA, the northern rangeland regions of WA had lower prevalence (1.9%) than the southern agriculture regions (10.7%). Seasonally, there was a peak prevalence in the spring dropping through the summer and autumn and rising again in the winter. This seasonal pattern was also found in the combined data for all sites in the 1990s. There was no gender difference in prevalence of CAdV either overall or in different regions. The overall prevalence of antibody to CaHV-1 was 2.2% (28/1300). The small number of positives allowed only limited statistical analysis that did not reveal any differences in decade of collection, age, season or region.
CONCLUSIONS: CAdV infection is common in the Australian fox population whereas CaHV-1 infection is rare. For CAdV, the age and seasonal patterns of seroprevalence were generally consistent with the recruitment of young susceptible foxes into the population in the spring and the accumulation of infections with age. The differences in regional prevalences correlated with fox density. The low prevalence of antibody to CaHV-1 suggests that CaHV-1 may be a more suitable vector than CAdV for bait delivery of immunocontraceptive antigens to foxes in Australia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986915     DOI: 10.1111/j.1751-0813.2005.tb15634.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  4 in total

1.  Sequential circulation of canine adenoviruses 1 and 2 in captive wild carnivores, France.

Authors:  Giulia Dowgier; Jennifer Lahoreau; Gianvito Lanave; Michele Losurdo; Katia Varello; Maria Stella Lucente; Gianluca Ventriglia; Elena Bozzetta; Vito Martella; Canio Buonavoglia; Nicola Decaro
Journal:  Vet Microbiol       Date:  2018-05-31       Impact factor: 3.293

2.  The relationship between reported domestic canine parvovirus cases and wild canid distribution.

Authors:  Alicia Van Arkel; Mark Kelman; Peter West; Michael P Ward
Journal:  Heliyon       Date:  2019-09-23

Review 3.  Difference Analysis Between Canine Adenovirus Types 1 And 2.

Authors:  Yanzhu Zhu; Jinfeng Xu; Shizhen Lian; Rui Zhang; Jinyu Hou; Minchun Wang; Xijun Yan
Journal:  Front Cell Infect Microbiol       Date:  2022-03-11       Impact factor: 5.293

Review 4.  Canine adenoviruses and herpesvirus.

Authors:  Nicola Decaro; Vito Martella; Canio Buonavoglia
Journal:  Vet Clin North Am Small Anim Pract       Date:  2008-07       Impact factor: 2.093

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.